
Supriya Lifescience Q3 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
Yes
Capex
Yes
3 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 2- Supriya Lifescience aims to achieve INR 1,000 crores+ revenue by FY'27, driven by existing products, new product launches, and CDMO/CMO business.
- Sustained year-on-year revenue growth of 20%-23% is targeted over the next three years.
- Contribution from CMO/CDMO, especially the anaesthetic product (a $300 million global market), is expected to be significant and could exceed conservative projections.
- Existing top products are growing at 5%-10%, with some products growing at around 8%-10%.
- Addition of 4-5 new products annually via enhanced R&D.
- Europe sales have increased substantially, indicating improved traction in regulated markets like Europe and North America.
- Capacity expansion (including new module E with 350 KL added capacity) will double overall capacity, supporting volume growth.
- New product categories include anaesthetics, anti-diabetic, and anti-anxiety therapies.
See what Supriya Lifescience management said on margin guidance — free account, 30 seconds.
Fundraise plans
YesSee what Supriya Lifescience management said on order book — free account, 30 seconds.
Capex plans
Yes- Planned capex of around INR 105-120 crores in Q1 FY'25, mainly for Module E at the Lote Parshuram site.
- Majority of this capex funded from IPO proceeds.
- Module E is a new dedicated production block with ~350 KL capacity, expected operational by Q1 FY'25.
- Ambernath greenfield site refurbished for bottling activities and API R&D; operational also by Q1 FY'25.
- Additional INR 60 crores capex over the next two years planned for Ambernath site to support CDMO/CMO activities, especially anaesthetic product bottling.
- Refurbishment planned for older modules (ABC) in the next fiscal.
- Capex expansion is modular and phased, aligned with utilization and orders.
- Asset turns target of 2.5x and above from this capex.
- Expansion aims to support revenue growth to INR 1,000 crores by FY'27 and strengthen backward integration and new product launches.
Track Supriya Lifescience — get its next earnings analysis in your feed
How does Supriya Lifescience rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Supriya Lifescience rank in Pharmaceuticals & Biotechnology?
Compare Supriya Lifescience against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Supriya Lifescience's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem